• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Novo Nordisk A>Novo Nordisk A/S ADR

Novo Nordisk A/S ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  1. Moats and Growth Drivers Look Solid for Post-Split Baxter

    Focus remains on hemophilia competition, but Baxter's comprehensive product portfolios are unmatched.

  2. Makings of a Wide Moat in Diabetes Care

    Novel products will allow drug firms to achieve price premiums on diabetes drugs in the U.S. and at least retain level pricing internationally.

  3. Strong Pipeline Helps Protect Baxter's Wide Moat From Competition

    The diversified health-care firm remains remarkably profitable in tough industries.

  4. Wide Moats, Positive Moat Trends, Exemplary Stewardship

    Morningstar StockInvestor editor Matt Coffina highlights three of the highest-quality companies we cover.

  5. Novo's Scale Advantages and Drug Lineup Broaden Its Wide Moat

    Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.

  6. Ideas From the Wide Moat Focus Index

    Morningstar StockInvestor editor Matt Coffina discusses recent additions to the Wide Moat Focus Index.

  7. Announcing Morningstar's Fund Managers of the Year for 2012

    These skippers shone amid a challenging market environment.

  8. What We Can Expect From Second-Quarter Earnings

    Morningstar's Heather Brilliant says investors could see a lot of market volatility this upcoming earnings season, but that could make for tremendous buying opportunities of quality names.

  9. Where It Could Pay to Be Active

    A look at how our 2012 Fund Managers of the Year stack up against their benchmarks.

  10. Readers Share Top Picks for an Uninspiring Market

    Some users find value in dividend-paying blue chips, while others are compiling watchlists and waiting for a pullback.

Upcoming Events

©2014 Morningstar Advisor. All right reserved.